Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Highnoon Laboratories's Margin of Safety % (DCF FCF Based) using Discounted FCF model is
-143.29%.
Highnoon Laboratories Margin of Safety % (DCF FCF Based) Related Terms
KAR:HINOON vs LLY, JNJ, ABBV: Margin of Safety % (DCF FCF Based) Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Margin of Safety % (DCF FCF Based) distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Margin of Safety % (DCF FCF Based) falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.
What does a Margin of Safety % (DCF FCF Based) of -143.29% mean?
Highnoon Laboratories (KAR:HINOON) has a Margin of Safety % (DCF FCF Based) of -143.29% as of Jul. 25, 2026. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Highnoon Laboratories.
Is Highnoon Laboratories' Margin of Safety % (DCF FCF Based) too high?
Highnoon Laboratories' current Margin of Safety % (DCF FCF Based) is -143.29%. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Margin of Safety % (DCF FCF Based) compare to LLY and JNJ?
Highnoon Laboratories' Margin of Safety % (DCF FCF Based) of -143.29% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF FCF Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF FCF Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF FCF Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF FCF Based) mean?
A high Margin of Safety % (DCF FCF Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Highnoon Laboratories. Highnoon Laboratories's current Margin of Safety % (DCF FCF Based) is -143.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current Margin of Safety % (DCF FCF Based) is -143.29%. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF FCF Based) calculated?
Margin of Safety % (DCF FCF Based) is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Margin of Safety % (DCF FCF Based) is -143.29% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Margin of Safety % (DCF FCF Based): -143.29%
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
